23andMe to Report FY2024 Third Quarter Financial Results
January 24, 2024 16:05 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts
December 19, 2023 08:00 ET
|
23andMe, Inc.
Thirty additional patients with advanced neuroendocrine and advanced ovarian cancer will be enrolled in the study of 23ME-00610, an investigational antibody targeting CD200R1 A second potentially...
23andMe Reports Second Quarter Fiscal 2024 Financial Results
November 08, 2023 16:05 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second...
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership
November 07, 2023 08:00 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total...
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
November 06, 2023 08:00 ET
|
23andMe, Inc.
23andMe presented data from the now completed dose escalation phase, and pharmacokinetic / pharmacodynamic (PK/PD) cohorts at the Society for Immunotherapy of Cancer Annual Meeting 2023 Dosing with...
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
October 31, 2023 08:00 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched Health Action Plan,...
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
October 30, 2023 08:00 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”) today announced a new, non-exclusive data license with GSK plc (LSE/NYSE: GSK) which...
23andMe to Report FY2024 Second Quarter Financial Results
October 25, 2023 16:05 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
September 27, 2023 16:05 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster...
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
September 14, 2023 07:00 ET
|
23andMe, Inc.
23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry or ancestry from a region where sickle cell...